FIELD: medicine.
SUBSTANCE: patients suffering stomach cancer are examined for a marker of proliferative activity Ki-67 and markers of apoptosis p53 and bcl-2. That is combined with immunohistological analysis to determine the absolute values in signet ring cell carcinoma: p53 - 10%, bcl-2 -10%, Ki-67 - 12%; in carcinoma simplex: p53 - 13%, bcl-2 11%, Ki-67 - 9%; in adenocarcinoma: p53 - 10%, bcl-2 - 9%, Ki-67 - 12% enabling to predict the onset of metastases in lymph nodes. The values p53 - 6%, bcl-2 -5%, Ki-67 - 10% provide to predict the absence of metastatic lesions in lymph nodes.
EFFECT: these predictors enable predicting an outcome of the disease, a survival rate and a probability of metastases in the untreated patients with planning of therapeutic actions.
1 tbl, 3 ex, 5 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR ESTIMATING SKIN MELANOMA NEOADJUVANT TREATMENT EFFECTIVENESS | 2006 |
|
RU2322194C1 |
| METHOD FOR DETECTING EFFICIENCY OF ANTI-TUMOR THERAPY OF SKIN MELANOMAS | 2004 |
|
RU2280483C2 |
| METHOD FOR DETERMINING AUTOHEMOCHEMOTHERAPY EFFECTIVENESS IN TREATING THE CASES OF CARCINOMA AFFECTING RECTOSIGMOID PORTION OF THE RECTUM AND SIGMOID COLON AND AUTOHEMOCHEMOTHERAPY COMBINED WITH ULTRAHIGH FREQUENCY HYPERTHERMIA IN TREATING THE CASES OF RECTAL CARCINOMA | 2001 |
|
RU2219553C2 |
| METHOD OF EVALUATING EFFICIENCY OF INTRAMURAL AUTOPLASMOCHEMICAL THERAPY OF URINE BLADDER CANCER | 2009 |
|
RU2398517C1 |
| METHOD FOR DIFFERENTIAL DIAGNOSTIC OF HIGH-GRADE DIFFERENTIATED ADENOCARCINOMAS AND ADENOMAS OF COLON | 2015 |
|
RU2599101C1 |
| METHOD FOR EVALUATING THE DEGREE OF RISK OF ADVERSE EVALUATION OF DISEASE IN PATIENTS WITH GASTRIC CANCER | 2016 |
|
RU2662085C1 |
| METHOD FOR PREDICTION OF RECURRENT SOFT TISSUE SARCOMAS | 2013 |
|
RU2532332C1 |
| METHOD OF CHOOSING A THERAPEUTIC APPROACH TO PATIENTS WITH REGIONAL LYMPHADENOPATHY OF UNKNOWN ORIGIN IN GASTRIC ADENOCARCINOMA | 2020 |
|
RU2740145C1 |
| METHOD FOR PREDICTING THE DEVELOPMENT OF METASTASES IN REGIONAL LYMPH NODES IN PATIENTS WITH GASTRIC ADENOCARCINOMA | 2017 |
|
RU2661600C1 |
| TEST SYSTEM “HV2 mtDNA-PCR” FOR PREDICTING THE DEVELOPMENT OF METASTASES IN PATIENTS WITH GASTRIC CANCER | 2017 |
|
RU2683571C1 |
